Jul 18, 2018
Alliance for Cancer Gene Therapy (ACGT) has announced the appointment of Nori Kasahara, MD, PhD to its Scientific Advisory Council (SAC). Noriyuki Kasahara is a Professor of Cell Biology & Pathology at the University of Miami and served as Co-Leader of the Viral Oncology Program at the Sylvester Comprehensive Cancer Center. Prior to this, he was Professor of Medicine & Molecular Pharmacology at the University of California, Los Angeles (UCLA), where he was Director of the UCLA Vector Core & Shared Resource facility at the Jonsson Comprehensive Cancer Center for over a decade. He continues to move the field forward with innovative science and practical approaches to cancer therapeutics. Dr. Kasahara has more than 30 years of experience and has authored more than 140 peer-reviewed articles in the fields of gene therapy and genetic engineering. He pioneered the development of tumor-selective retroviral replicating vectors (RRV) for gene therapy of cancer, now in first-in-human multi-center clinical trials sponsored by Tocagen Inc. He received a Clinical Investigator Grant from ACGT in 2017 to advance a clinical trial for virotherapy of glioblastoma.
Joseph Glorioso, PhD, Chairman of ACGT’s SAC, remarked, “It is a great honor to have Nori Kasahara join ACGT’s Scientific Advisory Council. Nori is known worldwide for his many contributions to cancer gene therapy and has made a tremendous impact on progress in the field of immuno-oncology. He has co-founded a number of biotech companies related to treatment of cancer and one of these, Tocagen Inc., is now a public company that has achieved substantial success in the treatment of glioblastoma. As a member of our SAC, he will utilize his deep knowledge and experience from the field to help ensure ACGT funds the most promising gene therapy research in areas where the support is needed most.”